MedTrace Logo

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19

NCT04895449 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2023-01-18

No results posted yet for this study

Summary

Multi-center phase Ib study to evaluate the Modified Vaccinia Virus Ankara (MVA) vaccine against SARS-CoV-2 in seronegative (Part A) and previously SARS-CoV-2-vaccinated individuals (Part B).

Conditions

  • Covid19

Interventions

BIOLOGICAL

MVA-SARS-2-ST

i.m. vaccine administration

Sponsors & Collaborators

  • German Center for Infection Research

    collaborator OTHER

  • Philipps University Marburg

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • IDT Biologika

    collaborator UNKNOWN

  • Clinical Trial Center North (CTC North GmbH & Co. KG)

    collaborator OTHER

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Marylyn M Addo, MD · Universitätsklinikum Hamburg-Eppendorf

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-16
Primary Completion
2022-11-02
Completion
2022-11-08

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04895449 on ClinicalTrials.gov